Fastpartner

Fastpartner

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Fastpartner - Positive development on IFPM guidance NTM

03 juli 2026

  • Solid letting activity, but timing/impact uncertain
  • Lower interest rate assumptions and SBBs drive estimates
  • 2026e P/CEPS of 11x vs coverage average of 14x

Softer top-line, lower operating costs

Fastpartner delivered Q2 NOI largely in line with us and Factset cons., where a slightly softer top-line was mitigated by lower costs. Central admin costs were in line with our estimate, while net financials were markedly higher, despite average paid interest compressing 10bp to 3.8% q-o-q. The result was rec. PTP 5% below our forecast. NAV (ABGSC definition) was 1.5% below our forecast, driven by negative value changes of SEK 220m, where property values in Kista dropped by 12% q-o-q. We make CEPS revisions of 0-4%, driven by lower assumed rates, SBBs during the quarter and timing of lettings.

Solid activity but low insight on actual impact

Q2 was active in terms of lettings, the largest was the 15k sqm letting to MagasinX in Frihamnen, another was HM Studios which expanded its lease by 3k sqm. So letting activity looks solid, but data points on rent levels, investment volumes, etc. is scarce, making it very difficult to assess the financial impact. And, as the company does not report net letting, visibility on top-line progression is low. Guidance on IFPM NTM was +1% q-o-q to SEK 790m, with market rates down sequentially we expect this explains the bulk of the positive development. On another note, following the appointment of a new CEO, the company is reviewing the portfolio with divestment likely to follow, no volume indicated. The CEO also announced a 100MW pipeline of potential of data center projects, but no indication of timeline or investment volumes.

'26e P/CEPS of 11x, coverage average of 14x

The share is trading at '26e P/CEPS of 11x, below the average in our coverage of 14x and the average for office peers in our coverage at 14x. On '26e P/EPRA NRV, the share is trading at 0.4x compared to office peers at 0.6x.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-08-25 Isofol Medical - Maximising the dose before Phase 2 Isofol Medical Analys
2026-08-24 Skolon - Broad-based growth continues Skolon Analys
2026-08-24 Gentoo Media - FCF generation remains top priority Gentoo Media Analys
2026-08-24 Impact Coatings - Backlog to carry H2e Impact Coat.. Analys
2026-08-24 I-tech - Beyond a single molecule I-tech Analys
2026-08-23 Catella - Signs of improvement, but delivery stil... Catella Analys
2026-08-23 Ogunsen - Some signs of stabilisation Ogunsen Analys
2026-08-21 Clavister - Strong quarter strengthens the outlook Clavister Analys
2026-08-21 Generic - Investing while growing Generic Analys
2026-08-21 Impact Coatings - A quarter driven by Coating Ser... Impact Coat.. Analys
2026-08-21 Skolon - Sweden profitability gains continue Skolon Analys
2026-08-21 I-tech - Strongest quarter on record I-tech Analys
2026-08-20 Tempest Security - Patrols below plan Tempest Sec.. Analys
2026-08-20 Tempest Security - Progress made but expectations... Tempest Sec.. Analys
2026-08-20 Ascelia Pharma - Still alive: Fighting to reverse... Ascelia Pharma Analys
2026-08-20 Clavister - Defence drives record quarter Clavister Analys
2026-08-20 Catella - Q2 softer than expected, but underlying... Catella Analys
2026-08-20 Generic - Volumes continue to grow Generic Analys
2026-08-19 SinterCast - Past the trough, but recovery pace u... SinterCast Analys
2026-08-19 Xplora Technologies - EBITDA -13% on soft senior ... Xplora Tech.. Analys